Zhejiang Xianju Pharmaceutical Co.,Ltd.

Equities

002332

CNE100000K64

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
12.16 CNY -0.82% Intraday chart for Zhejiang Xianju Pharmaceutical Co.,Ltd. -1.94% -4.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Xianju Pharmaceutical Co.,Ltd. Announces 2023 Final Profit Distribution on A Shares, Payable on 05 June 2024 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year 2023 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year 2023 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xianju Pharma to Invest 33 Million Yuan in Local Drug R&D Firm MT
Hangzhou Yuhong Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 80 million in funding from Zhejiang Xianju Pharmaceutical Co.,Ltd., Jiaxing Miyin Yuhong Equity Investment Partnership Enterprise (L.P.), Hainan Huishengde Enterprise Management Partnership Enterprise (L.P.), Hangzhou Yulin Enterprise Management Partnership Enterprise (L.P.) CI
Zhejiang Xianju Pharmaceutical's Flumazenil Injection Chosen for China's Centralized Bid MT
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 02 June 2023 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year 2022 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Proposes Final Dividend for 2022 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Xianju Pharma’s Abortion Tablet Passes Consistency Evaluation MT
Zhejiang Xianju Pharma Logs 20.4% Jump in 2022 Profit MT
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Ningbo Linghan Enterprise Management Partnership Enterprise (Limited Partnership) entered into equity transaction contract to acquire 14.60% stake in Hangzhou Weisibo Medical Technology Co., Ltd. from Zhejiang Xianju Pharmaceutical Co.,Ltd. for CNY 8 million. CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves Management Elections CI
Zhejiang Xianju Pharmaceutical Co.,Ltd.(SZSE:002332) dropped from Shenzhen Stock Exchange Component A Share Index CI
Zhejiang Xianju Pharmaceutical Co.,Ltd.(SZSE:002332) dropped from Shenzhen Stock Exchange Component Index CI
Zhejiang Xianju Pharmaceutical Receives Regulatory Approval for Injection MT
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 8, 2022 CI
Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves 2021 Profit Distribution Plan CI
Chart Zhejiang Xianju Pharmaceutical Co.,Ltd.
More charts
ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the research, manufacture and distribution of steroid active pharmaceutical ingredients (APIs) and preparations. The Company's products are mainly categorized into cortex hormone drugs, gynecology and family planning drugs, as well as anesthesia drugs and muscle relaxants. The Company is also involved in the provision of respiratory drugs, immunomodulators, dermatology drugs, anaesthetic drugs and others. The Company distributes its products in domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.16 CNY
Average target price
15.21 CNY
Spread / Average Target
+25.08%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002332 Stock
  4. News Zhejiang Xianju Pharmaceutical Co.,Ltd.
  5. Zhejiang Xianju Pharma Logs 20.4% Jump in 2022 Profit